In 129 older patients with relapsed/refractory follicular lymphoma responding to induction, rituximab-lenalidomide maintenance did not significantly improve 2-year PFS vs rituximab alone (73% vs 64%); grade 3/4 adverse events were more frequent.
RCTn = 129
Botto et al. RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma